Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Should Release Existing Supply Of Primatene Mist OTC Asthma Inhaler, Rep. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Lawmakers seek to restore the availability of Primatene Mist while the absence of an alternative OTC asthma remedy persists.

You may also be interested in...

Primatene Mist Chances To Remain On Market Dwindle With Senate Vote

FDA Expectation For Replacement OTC Inhaler Remains Unfulfilled

The only inhalers to treat asthma available after Dec. 31 will be prescription products.

Coalition Pushes Congress On OTC Purchases With Health Savings Accounts

The Health Choices Coalition sent letters urging House and Senate members to support legislation that would strike the health care reform law requirement that consumers obtain a prescription in order to purchase OTCs with a pre-tax savings account.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts